| Literature DB >> 22028943 |
Victoria Wahl-Jensen1, Sabine Kurz, Friedericke Feldmann, Lukas K Buehler, Jason Kindrachuk, Victor DeFilippis, Jean da Silva Correia, Klaus Früh, Jens H Kuhn, Dennis R Burton, Heinz Feldmann.
Abstract
Zaire ebolavirus (ZEBOV) infections are associated with high lethality in primates. ZEBOV primarily targets mononuclear phagocytes, which are activated upon infection and secrete mediators believed to trigger initial stages of pathogenesis. The characterization of the responses of target cells to ZEBOV infection may therefore not only further understanding of pathogenesis but also suggest possible points of therapeutic intervention. Gene expression profiles of primary human macrophages exposed to ZEBOV were determined using DNA microarrays and quantitative PCR to gain insight into the cellular response immediately after cell entry. Significant changes in mRNA concentrations encoding for 88 cellular proteins were observed. Most of these proteins have not yet been implicated in ZEBOV infection. Some, however, are inflammatory mediators known to be elevated during the acute phase of disease in the blood of ZEBOV-infected humans. Interestingly, the cellular response occurred within the first hour of Ebola virion exposure, i.e. prior to virus gene expression. This observation supports the hypothesis that virion binding or entry mediated by the spike glycoprotein (GP(1,2)) is the primary stimulus for an initial response. Indeed, ZEBOV virions, LPS, and virus-like particles consisting of only the ZEBOV matrix protein VP40 and GP(1,2) (VLP(VP40-GP)) triggered comparable responses in macrophages, including pro-inflammatory and pro-apoptotic signals. In contrast, VLP(VP40) (particles lacking GP(1,2)) caused an aberrant response. This suggests that GP(1,2) binding to macrophages plays an important role in the immediate cellular response.Entities:
Mesh:
Year: 2011 PMID: 22028943 PMCID: PMC3196478 DOI: 10.1371/journal.pntd.0001359
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1Color-coded hierarchical cluster analysis.
Threshold Criteria: changes of gene expression levels in primary macrophages of at least 2-fold (“threshold”) occurring in at least two of the three donors in at least one of the two time points upon Ebola virion exposure compared to mock exposure. Gene subcluster 1 is characterized by expression variability across donors and time points. Subcluster 2 is characterized by consistent responses among all 3 donors in at least one time point.
Figure 2Cluster analysis of genes selected by Trend Criteria.
Changes of gene expression levels occurred in primary macrophages from all three donors (“trend”) in at least one time point in the same direction with p-values<0.01. Red and green colors represent upregulation and downregulation, respectively. Intensity of colors reflects intensity of changes in gene expression.
Figure 3Functional networks associated with differentially expressed host gene expression 1 h and 6 h post-infection.
The intensity of the node color indicates the degree of up (red)- or down (green)-regulation. Genes in uncolored nodes were not identified as differentially expressed in our experiment and were integrated into the computationally generated networks on the basis of the evidence stored in the IPA knowledge memory indicating a relevance to this network. A. Network 1 at 1 h post-infection - Cell-To-Cell Signaling and Interaction, Hematological System Development and Function, Immune Cell Trafficking; B. Network 2 at 1 h post-infection – Inflammatory Response, Cellular Movement, Hematological System Development and Function; C. Network 3 at 1 h post-infection – Cellular Movement, Hematological System Development and Function, Immune Cell Trafficking. D. Network 1 at 6 h post-infection - Cell-To-Cell Signaling and Interaction, Hematological System Development and Function, Immune Cell Trafficking; E. Network 2 at 6 h post-infection – Inflammatory Response, Cellular Movement, Hematological System Development and Function; F. Network 3 at 6 h post-infection – Cellular Movement, Hematological System Development and Function, Immune Cell Trafficking.
Differential host signaling pathway modulation in Ebola-infected cells 1 h post-infection.
| Pathway Name | Source Name | Genes in Pathway | Genes With Increased Expression | Up-Regulated PathwayP Value | Genes With Decreased Expression | Down-Regulated PathwayP Value |
| Heterotrimeric GPCR signaling pathway (through G alpha s ACs PKA BRaf and ERK cascade)(canonical) (GPCR signaling (G alpha s, PKA and ERK)) | INOH | 43 | 16 | 0.00088 | 4 | 0.93421 |
| Heterotrimeric GPCR signaling pathway (through G alpha i and pertussis toxin) (GPCR signaling (pertussis toxin)) | INOH | 37 | 14 | 0.00156 | 3 | 0.95254 |
| Heterotrimeric GPCR signaling pathway (through G alpha s ACs Epac BRaf and ERKcascade) (GPCR signaling (G alpha s, Epac and ERK)) | INOH | 37 | 14 | 0.00156 | 3 | 0.95254 |
| Heterotrimeric GTP-binding protein coupled receptor signaling pathway (through G alpha i, adenylate cyclase and cAMP) (GPCR signaling (G alpha i)) | INOH | 37 | 14 | 0.00156 | 3 | 0.95254 |
| Heterotrimeric GTP-binding protein coupled receptor signaling pathway (through G alpha s, cholera toxin, adenylate cyclase and cAMP) (GPCR signaling (cholera toxin)) | INOH | 40 | 14 | 0.00370 | 3 | 0.96827 |
| Heterotrimeric GPCR signaling pathway (through G alpha q, PLC beta and ERK cascade) (GPCR signaling (G alpha q)) | INOH | 42 | 14 | 0.00613 | 2 | 0.99481 |
| Dilated cardiomyopathy | KEGG | 15 | 7 | 0.00674 | 2 | 0.72108 |
| Jak-STAT signaling pathway | KEGG | 47 | 15 | 0.00725 | 3 | 0.98807 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | KEGG | 12 | 6 | 0.00814 | 1 | 0.87865 |
| IL27-mediated signaling events | PID NCI | 13 | 6 | 0.01302 | 0 | 1 |
| ATF-2 transcription factor network | PID NCI | 17 | 7 | 0.01507 | 1 | 0.95001 |
| African trypanosomiasis | KEGG | 17 | 7 | 0.01507 | 0 | 1 |
| Graft-versus-host disease | KEGG | 7 | 4 | 0.01818 | 1 | 0.70683 |
| Calcium signaling in the CD4+ TCR pathway | PID NCI | 11 | 5 | 0.02529 | 0 | 1 |
| Cytokine-cytokine receptor interaction | KEGG | 73 | 19 | 0.02729 | 8 | 0.92362 |
| Amine ligand-binding receptors | REACTOME | 2 | 2 | 0.02846 | 0 | 1 |
| Dissolution of Fibrin Clot | REACTOME | 2 | 2 | 0.02846 | 0 | 1 |
| Dual incision reaction in TC-NER | REACTOME | 2 | 2 | 0.02846 | 0 | 1 |
| Fibrinolysis pathway | PID BIOCARTA | 2 | 2 | 0.02846 | 0 | 1 |
| Formation of transcription-coupled NER (TC-NER) repair complex | REACTOME | 2 | 2 | 0.02846 | 0 | 1 |
| IL-2 signaling pathway (JAK1 JAK3 STAT5) (IL-2 signaling (JAK1 JAK3 STAT5)) | INOH | 2 | 2 | 0.02846 | 0 | 1 |
| Multi-drug resistance factors | PID BIOCARTA | 2 | 2 | 0.02846 | 0 | 1 |
| Allograft rejection | KEGG | 8 | 4 | 0.03163 | 1 | 0.75415 |
| IL12-mediated signaling events | PID NCI | 24 | 8 | 0.03646 | 2 | 0.91823 |
| Class B/2 (Secretin family receptors) | REACTOME | 5 | 3 | 0.03654 | 0 | 1 |
| IL23-mediated signaling events | PID NCI | 20 | 7 | 0.03829 | 1 | 0.97070 |
| Malaria | KEGG | 20 | 7 | 0.03829 | 1 | 0.97070 |
| Negative feedback regulation of JAK STAT pathway by (cytokine receptor degradation signaling) (JAK-STAT pathway and regulation pathway Diagram) | INOH | 21 | 7 | 0.04948 | 1 | 0.97549 |
| Type I diabetes mellitus | KEGG | 9 | 4 | 0.04956 | 1 | 0.79387 |
| Coregulation of Androgen receptor activity | PID NCI | 10 | 1 | 0.84457 | 5 | 0.01268 |
| S1P4 pathway | PID NCI | 4 | 0 | 1 | 3 | 0.01430 |
| Amine compound SLC transporters | REACTOME | 2 | 0 | 1 | 2 | 0.02556 |
| Na+/Cl− dependent neurotransmitter transporters | REACTOME | 2 | 0 | 1 | 2 | 0.02556 |
| Overview of telomerase rna component gene hterc transcriptional regulation | PID BIOCARTA | 2 | 0 | 1 | 2 | 0.02556 |
| Regulation of CDC42 activity | PID NCI | 2 | 0 | 1 | 2 | 0.02556 |
| Metabolism of non-coding RNA | REACTOME | 8 | 0 | 1 | 4 | 0.02632 |
| SnRNP Assembly | REACTOME | 8 | 0 | 1 | 4 | 0.02632 |
| N-Glycan biosynthesis | KEGG | 5 | 0 | 1 | 3 | 0.03156 |
| Negative regulation of (G alpha i GDP-GTP exchange signaling) (GPCR signaling (G alpha i)) | INOH | 5 | 0 | 1 | 3 | 0.03156 |
| Negative regulation of (G alpha i GDP-GTP exchange signaling) (GPCR signaling (pertussis toxin)) | INOH | 5 | 0 | 1 | 3 | 0.03156 |
| RNA transport | KEGG | 21 | 1 | 0.98041 | 7 | 0.03816 |
| CXCR3-mediated signaling events | PID NCI | 9 | 1 | 0.81260 | 4 | 0.04155 |
| Metabolism of RNA | REACTOME | 13 | 1 | 0.91143 | 5 | 0.04308 |
Differential host signaling pathway modulation identified by pathway ORA through the direct comparison of mock-infected and EBOV-infected macrophages 1 hr post-infection. The online software InnateDB was utilized for pathway over-representation analysis. Based on levels of differential expression InnateDB is able to predict pathways that are consistent with the experimental data. Pathways are assigned a probability value (p) based on the number of proteins present for a particular pathway. It also provides the number of uploaded pathways associated with a particular pathway as well as the subset of individual genes that are differentially expressed.
Differential host signaling pathway modulation in Ebola-infected cells 6 h post-infection.
| Pathway Name | Source Name | Genes in Path-way | Genes With Increased Expression | Up-Regulated PathwayP Value | Genes With Decreased Expression | Down-Regulated PathwayP Value |
| Syndecan-1-mediated signaling events | PID NCI | 5 | 5 | 0.00023 | 0 | 1 |
| Cytokine-cytokine receptor interaction | KEGG | 73 | 25 | 0.00095 | 7 | 0.99528 |
| Signaling by GPCR | REACTOME | 56 | 20 | 0.00178 | 11 | 0.56426 |
| Chemokine signaling pathway | KEGG | 55 | 19 | 0.00362 | 5 | 0.99167 |
| Nicotinate and Nicotinamide metabolism | INOH | 5 | 4 | 0.00536 | 0 | 1 |
| Peptide ligand-binding receptors | REACTOME | 20 | 9 | 0.00644 | 4 | 0.57903 |
| Prostaglandin and Leukotriene metabolism | INOH | 3 | 3 | 0.00673 | 0 | 1 |
| Chemokine receptors bind chemokines | REACTOME | 12 | 6 | 0.01446 | 2 | 0.71951 |
| Nicotinate and nicotinamide metabolism | KEGG | 4 | 3 | 0.02315 | 0 | 1 |
| G alpha (q) signalling events | REACTOME | 21 | 8 | 0.03083 | 2 | 0.94103 |
| Cardiac muscle contraction | KEGG | 2 | 2 | 0.03581 | 0 | 1 |
| Lysosphingolipid and LPA receptors | REACTOME | 2 | 2 | 0.03581 | 0 | 1 |
| Regulation of CDC42 activity | PID NCI | 2 | 2 | 0.03581 | 0 | 1 |
| Regulation of beta-cell development | REACTOME | 2 | 2 | 0.03581 | 0 | 1 |
| CD4 T cell receptor signaling (through Vav, Rac and JNK cascade (CD4 T cell receptor signaling (JNK cascade)) | INOH | 11 | 5 | 0.04013 | 2 | 0.67174 |
| Antigen processing and presentation | KEGG | 8 | 4 | 0.04658 | 2 | 0.48975 |
| Arachidonic acid metabolism | KEGG | 5 | 3 | 0.04984 | 1 | 0.66788 |
| Steroid hormone biosynthesis | KEGG | 5 | 3 | 0.04984 | 1 | 0.66788 |
| RNA Polymerase I Transcription | REACTOME | 5 | 0 | 1 | 4 | 0.00626 |
| ATP+ADP = ADP+ATP (Purine nucleotides and Nucleosides metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| ATP+CDP = ADP+CTP (Pyrimidine Nucleotides and Nucleosides metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| ATP+GDP = ADP+GTP (Folate metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| ATP+GDP = ADP+GTP (Purine nucleotides and Nucleosides metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| ATP+IDP = ADP+ITP (Purine nucleotides and Nucleosides metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| ATP+UDP = ADP+UTP (Pyrimidine Nucleotides and Nucleosides metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| ATP+dADP = ADP+dATP (Purine nucleotides and Nucleosides metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| ATP+dCDP = ADP+dCTP (Pyrimidine Nucleotides and Nucleosides metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| ATP+dGDP = ADP+dGTP (Purine nucleotides and Nucleosides metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| ATP+dIDP = ADP+dITP (Purine nucleotides and Nucleosides metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| ATP+dTDP = ADP+dTTP (Pyrimidine Nucleotides and Nucleosides metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| ATP+dUDP = ADP+dUTP (Pyrimidine Nucleotides and Nucleosides metabolism) | INOH | 3 | 0 | 1 | 3 | 0.00760 |
| Post-Elongation Processing of Intronless pre-mRNA | REACTOME | 3 | 0 | 1 | 3 | 0.00760 |
| Processing of Capped Intronless Pre-mRNA | REACTOME | 3 | 0 | 1 | 3 | 0.00760 |
| Processing of Intronless Pre-mRNAs | REACTOME | 3 | 0 | 1 | 3 | 0.00760 |
| Transcription | REACTOME | 20 | 2 | 0.91737 | 9 | 0.00852 |
| RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription | REACTOME | 9 | 0 | 1 | 5 | 0.01808 |
| Cleavage of Growing Transcript in the Termination Region | REACTOME | 4 | 0 | 1 | 3 | 0.02597 |
| MRNA 3′-end processing | REACTOME | 4 | 0 | 1 | 3 | 0.02597 |
| Post-Elongation Processing of Intron-Containing pre-mRNA | REACTOME | 4 | 0 | 1 | 3 | 0.02597 |
| Post-Elongation Processing of the Transcript | REACTOME | 4 | 0 | 1 | 3 | 0.02597 |
| RNA Polymerase I Promoter Clearance | REACTOME | 4 | 0 | 1 | 3 | 0.02597 |
| RNA Polymerase I Transcription Initiation | REACTOME | 4 | 0 | 1 | 3 | 0.02597 |
| RNA Polymerase I Transcription Termination | REACTOME | 4 | 0 | 1 | 3 | 0.02597 |
| RNA Polymerase II Transcription Termination | REACTOME | 4 | 0 | 1 | 3 | 0.02597 |
| Stabilization and accumulation of cytoplasmic beta-catenin (Canonical) (Canonical Wnt signaling pathway Diagram) | INOH | 4 | 1 | 0.56935 | 3 | 0.02597 |
| Stabilization and accumulation of cytoplasmic beta-catenin (Canonical) (Mammalian Wnt signaling pathway Diagram) | INOH | 4 | 1 | 0.56935 | 3 | 0.02597 |
| Stabilization and accumulation of cytoplasmic beta-catenin (Mammal) (Mammalian Wnt signaling pathway Diagram) | INOH | 4 | 1 | 0.56935 | 3 | 0.02597 |
| L1CAM interactions | REACTOME | 7 | 1 | 0.77162 | 4 | 0.03141 |
| Rb tumor suppressor/checkpoint signaling in response to dna damage | PID BIOCARTA | 7 | 0 | 1 | 4 | 0.03141 |
| Neuroactive ligand-receptor interaction | KEGG | 28 | 6 | 0.44392 | 10 | 0.03403 |
| Activated TAK1 mediates p38 MAPK activation | REACTOME | 2 | 0 | 1 | 2 | 0.03883 |
| Amine ligand-binding receptors | REACTOME | 2 | 0 | 1 | 2 | 0.03883 |
| Glutathione conjugation | REACTOME | 2 | 0 | 1 | 2 | 0.03883 |
| Leukotriene synthesis | REACTOME | 2 | 0 | 1 | 2 | 0.03883 |
| Multi-drug resistance factors | PID BIOCARTA | 2 | 0 | 1 | 2 | 0.03883 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | REACTOME | 2 | 0 | 1 | 2 | 0.03883 |
| Netrin mediated repulsion signals | REACTOME | 2 | 0 | 1 | 2 | 0.03883 |
| Polyadenylation of mrna | PID BIOCARTA | 2 | 0 | 1 | 2 | 0.03883 |
| Recycling of bile acids and salts | REACTOME | 2 | 0 | 1 | 2 | 0.03883 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | REACTOME | 2 | 0 | 1 | 2 | 0.03883 |
Differential host signaling pathway modulation identified by pathway ORA through the direct comparison of mock-infected and EBOV-infected macrophages 6 hr post-infection. The online software InnateDB was utilized for pathway over-representation analysis as in Table 1.
Figure 4Comparison of DNA microarray and real-time PCR data.
DNA microarray results and real-time RT-PCR quantification of changes in cellular expression levels of 16 selected human macrophages genes after 1 h (A) or 6 h (B) post exposure to Ebola virions. Data are expressed as fold-change of cellular gene expression. Data represent the median value for donors 1, 2, and 3.
Figure 5Strand-specific detection ZEBOV RNA.
Strand-specific detection of the negative-stranded genomic ZEBOV GP RNA and the positive-stranded ZEBOV GP cRNAs by real-time RT-PCR performed on RNA purified from macrophages of donors D2 and D4 at 1 h and 6 h after virion exposure. All values are normalized to total RNA.
Figure 6Determination of relative changes in expression levels of 21 cellular genes in primary human macrophages.
Depicted are fold-changes at the 1 h and 6 h time points after exposure to Ebola virions compared to mock-exposed cells, cells exposed to purified Ebola virion-like particles (VLPs) containing VP40 and GP1,2 (VLPVP40-GP) or VLPs containing VP40 only (VLPVP40), or cells treated with mock-VLP preparation. As controls, macrophages of each donor were treated in parallel with latex beads or with 10 ng of LPS. (A) Color-coded first dimension hierarchal cluster analysis based on average linkage clustering of the fold-changes in cellular gene expression in cells of donors D4, D5 and D6 at the 1 h and 6 h time points. Ratios were calculated as log2 values. Positive values indicate upregulation as compared to mock infection/treatments and are represented by red coloration. Negative values indicate down regulation and are represented by green colors. White indicates no change in gene expression (log2 = 0). Each gene has been tested with 5 different stimuli (ZEBOV, VLPVP40-GP, VLPs VLPVP40, LPS, and neutral latex beads), in 3 donors at 2 time points (1 h and 6 h post infection). This provides a total of 30 different evaluations of changes in expression levels per gene. Blocks of three (1 h or 6 h for 3 donors) or six variables (e.g. VLP) can clearly be seen. (B) Color-coded second-dimensional clustering based on genes with similar changes in expression levels. Fold-changes in cellular gene expression following exposure to Ebola virions or treatment with VLPVP40-GP after 1 h (C) and 6 h (D) incubation of human macrophages from donors D4, D5 and D6. Data represent the median values of the fold-changes in log2 of cellular gene expression of donors D4–6.